649 related articles for article (PubMed ID: 28228078)
21. Solid lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics for the treatment of psoriasis.
Katari O; Jain S
Expert Opin Drug Deliv; 2021 Dec; 18(12):1857-1872. PubMed ID: 34823429
[TBL] [Abstract][Full Text] [Related]
22. Emerging Trends in Topical Delivery of Curcumin Through Lipid Nanocarriers: Effectiveness in Skin Disorders.
Waghule T; Gorantla S; Rapalli VK; Shah P; Dubey SK; Saha RN; Singhvi G
AAPS PharmSciTech; 2020 Oct; 21(7):284. PubMed ID: 33058071
[TBL] [Abstract][Full Text] [Related]
23. Comparison of ethosomes and liposomes for skin delivery of psoralen for psoriasis therapy.
Zhang YT; Shen LN; Wu ZH; Zhao JH; Feng NP
Int J Pharm; 2014 Aug; 471(1-2):449-52. PubMed ID: 24907596
[TBL] [Abstract][Full Text] [Related]
24. Nanostructured Lipid Carriers as Potential Drug Delivery Systems for Skin Disorders.
Waghule T; Rapalli VK; Gorantla S; Saha RN; Dubey SK; Puri A; Singhvi G
Curr Pharm Des; 2020; 26(36):4569-4579. PubMed ID: 32534562
[TBL] [Abstract][Full Text] [Related]
25. Recent Advancement in Topical Nanocarriers for the Treatment of Psoriasis.
Biswasroy P; Pradhan D; Kar B; Ghosh G; Rath G
AAPS PharmSciTech; 2021 May; 22(5):164. PubMed ID: 34041632
[TBL] [Abstract][Full Text] [Related]
26. Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis.
Fereig SA; El-Zaafarany GM; Arafa MG; Abdel-Mottaleb MMA
Drug Deliv; 2020 Dec; 27(1):662-680. PubMed ID: 32393082
[TBL] [Abstract][Full Text] [Related]
27. Nanocarriers Mediated Cutaneous Drug Delivery.
Güngör S; Kahraman E
Eur J Pharm Sci; 2021 Mar; 158():105638. PubMed ID: 33176190
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo trans-epidermal water loss evaluation following topical drug delivery systems application for pharmaceutical analysis.
Cristiano MC; Froiio F; Mancuso A; Iannone M; Fresta M; Fiorito S; Celia C; Paolino D
J Pharm Biomed Anal; 2020 Jul; 186():113295. PubMed ID: 32361608
[TBL] [Abstract][Full Text] [Related]
29. Treatment Modalities of Psoriasis: A Focus on Requisite for Topical Nanocarrier.
Ramanunny AK; Wadhwa S; Thakur D; Singh SK; Kumar R
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):418-433. PubMed ID: 32496998
[TBL] [Abstract][Full Text] [Related]
30. Targeted cutaneous delivery of ciclosporin A using micellar nanocarriers and the possible role of inter-cluster regions as molecular transport pathways.
Lapteva M; Santer V; Mondon K; Patmanidis I; Chiriano G; Scapozza L; Gurny R; Möller M; Kalia YN
J Control Release; 2014 Dec; 196():9-18. PubMed ID: 25278258
[TBL] [Abstract][Full Text] [Related]
31. Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy.
Parnami N; Garg T; Rath G; Goyal AK
Artif Cells Nanomed Biotechnol; 2014 Dec; 42(6):406-12. PubMed ID: 24079701
[TBL] [Abstract][Full Text] [Related]
32. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis.
Lapteva M; Mondon K; Möller M; Gurny R; Kalia YN
Mol Pharm; 2014 Sep; 11(9):2989-3001. PubMed ID: 25057896
[TBL] [Abstract][Full Text] [Related]
33. Lipid-Based Nanoparticles as Carriers for Dermal Delivery of Antioxidants.
Lucia M
Curr Drug Metab; 2017; 18(5):469-480. PubMed ID: 28228079
[TBL] [Abstract][Full Text] [Related]
34. Improved topical delivery of tacrolimus: A novel composite hydrogel formulation for the treatment of psoriasis.
Gabriel D; Mugnier T; Courthion H; Kranidioti K; Karagianni N; Denis MC; Lapteva M; Kalia Y; Möller M; Gurny R
J Control Release; 2016 Nov; 242():16-24. PubMed ID: 27639683
[TBL] [Abstract][Full Text] [Related]
35. Exploration of and insights into advanced topical nanocarrier systems for the treatment of psoriasis.
Zhang M; Hong S; Sun X; Zhou Y; Luo Y; Liu L; Wang J; Wang C; Lin N; Li X
Front Med (Lausanne); 2022; 9():1017126. PubMed ID: 36590975
[TBL] [Abstract][Full Text] [Related]
36. Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities.
Wan T; Pan W; Long Y; Yu K; Liu S; Ruan W; Pan J; Qin M; Wu C; Xu Y
Int J Nanomedicine; 2017; 12():1485-1497. PubMed ID: 28260894
[TBL] [Abstract][Full Text] [Related]
37. Management of nail psoriasis by topical drug delivery: a pharmaceutical perspective.
Thatai P; Khan AB
Int J Dermatol; 2020 Aug; 59(8):915-925. PubMed ID: 32239692
[TBL] [Abstract][Full Text] [Related]
38. Ethosomes and Transfersomes: Principles, Perspectives and Practices.
Garg V; Singh H; Bimbrawh S; Singh SK; Gulati M; Vaidya Y; Kaur P
Curr Drug Deliv; 2017; 14(5):613-633. PubMed ID: 27199229
[TBL] [Abstract][Full Text] [Related]
39. Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors.
Katare OP; Raza K; Singh B; Dogra S
Indian J Dermatol Venereol Leprol; 2010; 76(6):612-21. PubMed ID: 21079304
[TBL] [Abstract][Full Text] [Related]
40. Efficacy study of vesicular gel containing methotrexate and menthol combination on parakeratotic rat skin model.
Nagle A; Goyal AK; Kesarla R; Murthy RR
J Liposome Res; 2011 Jun; 21(2):134-40. PubMed ID: 20557280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
